Breaking News

Icahn Takes 8.48% Stake in Hertz; May Seek Talks, Board Seat
Tweet TWEET

New Products, Positive Clinical Trial Results, FDA Submissions and Stock Price Updates - Research Report on Pfizer, Cubist,

New Products, Positive Clinical Trial Results, FDA Submissions and Stock Price
Updates - Research Report on Pfizer, Cubist, Zoetis, Edwards Lifesciences, and
                                  C.R. Bard

PR Newswire

NEW YORK, November 28, 2013

NEW YORK, November 28, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Zoetis Inc.
(NYSE: ZTS), Edwards Lifesciences Corp. (NYSE: EW) and C.R. Bard, Inc. (NYSE:
BCR). Today's readers may access these reports free of charge - including full
price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On November 25, 2013, Pfizer Inc. (Pfizer) introduced the Robitussin Maximum
Strength Cough + Chest Congestion DM, the Company's new liquid-filled capsules
that control cough on-the-go. According to the Company, the formulation not
only uses the power of Maximum Strength Robitussin cough liquid, but is a
convenient option for those hitting the road or boarding a plane during the
holiday season. Pfizer also said that families can track when cough activity
spikes in their local area through the Robitussin COUGHCAST tool, available on
the Robitussin website. As per Pfizer, the tool can let people know when cough
is most likely to strike, so they can be prepared to effectively treat their
symptoms. The Full Research Report on Pfizer Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/d702_PFE

--

Cubist Pharmaceuticals Inc. Research Report

On November 25, 2013, Cubist Pharmaceuticals Inc. (Cubist) announced top-line
results from the Company's pivotal Phase 3 clinical trial of its antibiotic
candidate ceftolozane/tazobactam in complicated urinary tract infections
(cUTI). Cubist said that ceftolozane/tazobactam met its primary endpoint of
statistical non-inferiority compared to lefloxacin (10% inferiority margin).
Cubist added that the primary endpoint is a composite of microbiological
eradication and clinical cure rate (composite cure rate) at 5-9 days after end
therapy (Test of Cure visit). Further, Cubist said that the 95% confidence
interval around the treatment difference had lower and upper bounds of 2.3%
and 14.6% respectively, favoring ceftolozane/tazobactam. In addition, the
Company said that ceftolozane/tazobactam is being developed for the potential
treatment of Hospital-Acquired Bacterial Pneumonia
(HABP)/Ventilator-Associated Bacterial Pneumonia (VABP), and expects to
initiate a pivotal Phase 3 trial to assess the safety and efficacy of the same
(at a dose of 3 g every 8 hours) in this indication during H1 2014. The Full
Research Report on Cubist Pharmaceuticals Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/92f2_CBST

--

Zoetis Inc. Research Report

On November 25, 2013, Zoetis Inc.'s stock declined 0.22%, ending the day at
$31.29. Over the previous three trading sessions, shares of Zoetis declined
0.26% compared to the S&P 500 which gained 1.19% during the same period. The
Full Research Report on Zoetis Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/7e25_ZTS

--

Edwards Lifesciences Corp. Research Report

On November 25, 2013, Edwards Lifesciences Corp.'s (Edwards Lifesciences)
stock declined 0.17%, ending the day at $64.75. Over the previous three
trading sessions, shares of Edwards Lifesciences gained 2.84% compared to the
S&P 500 which gained 1.19% during the same period. The Full Research Report on
Edwards Lifesciences Corp. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/48b8_EW

--

C.R. Bard, Inc. Research Report

On November 25, 2013, C.R. Bard, Inc. (Bard) announced that the Company's
Lutonix technology center submitted the final module of the pre-market
approval (PMA) application to the U.S. Food and Drug Administration (FDA) to
support approval for the Lutonix Drug-Coated PTA Dilatation Catheter (DCB).
According to the Company, the Lutonix DCB is being clinically evaluated in the
global, multicenter LEVANT 2 randomized clinical trial. The Company added that
the purpose of this pivotal investigational device exemption (IDE) trial is to
compare the safety and efficacy of the Lutonix DCB to standard angioplasty
balloons for the treatment of peripheral arterial disease (PAD) in superficial
femoral (SFA) and popliteal arteries. Timothy M. Ring, Chairman and CEO of
Bard, said, "This submission marks a key milestone in our drug-coated balloon
program, which continues to progress as expected. We look forward to
interfacing with the FDA for the purpose of making this important technology
available to U.S. patients." The Full Research Report on C.R. Bard, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/141e_BCR

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.